<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740296</url>
  </required_header>
  <id_info>
    <org_study_id>DENIM</org_study_id>
    <nct_id>NCT02740296</nct_id>
  </id_info>
  <brief_title>Depression and Immune Function in Multiple Sclerosis (MS)</brief_title>
  <acronym>DENIM</acronym>
  <official_title>Depression and Immune Function in Multiple Sclerosis (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is one of the most common symptoms of multiple sclerosis (MS) with a life-time
      prevalence of major depressive disorder (MDD) of up to 50%. Depression occurs more frequently
      in MS than in other chronic diseases including other neurological and inflammatory disorders
      and may contribute to lower quality of life, cognitive problems, difficulties at work, and
      poorer long term health outcomes. Despite its clinical relevance, the biological mechanisms
      which may be responsible for the high risk for MS patients to develop depression are unknown.

      In this observational study, investigators explore the molecular mechanisms responsible for
      the impaired regulation of immune cells in relapsing-remitting (RR) MS patients with
      depression. Investigators will compare the molecular and phenotypical profile of immune cells
      obtained from RRMS patients with clinical depression (n=50), matched MS patients who do not
      suffer from depression (n=50) as well as matched healthy controls (n=50) and matched patients
      with depression but without a comorbid neurological disorder (n=50).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Beck Depression Inventory - II</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RRMS</arm_group_label>
    <description>Relapsing-Remitting Multiple Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RRMS+MDD</arm_group_label>
    <description>Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD</arm_group_label>
    <description>Major Depressive Disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>RRMS</arm_group_label>
    <arm_group_label>RRMS+MDD</arm_group_label>
    <arm_group_label>MDD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited at neurological outpatient clinics and neurologcial clinics of
        the Charité and neurologists' medical practices.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing remitting MS by McDonald Criteria (for RRMS and RRMS+MDD groups).

          -  Currently meeting diagnostic criteria for Major Depressive Disorder (for MDD and
             RRMS+MDD groups)

          -  Age 18-55.

          -  On stable treatment regime, either untreated or on disease modifying therapy (DMT) for
             &gt; 6 months

        Exclusion Criteria:

          -  Secondary-progressive or primary progressive MS.

          -  Substance abuse for more than 6 months.

          -  Pregnancy

          -  Use of steroids or vaccination or infections in the previous 3 months.

          -  Signs of serious psychiatric pathology other than depression including schizophrenia,
             bipolar disorder or developmental and learning disorders including disorders on the
             autism spectrum

          -  Antidepressant medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

